Antibodies, Monoclonal, Humanized Concept

subject area of

• 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis  Academic Article
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis  Academic Article
• A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies  Academic Article
• A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice  Academic Article
• A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies  Academic Article
• A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207  Academic Article
• A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)  Academic Article
• A fatal case of Pneumocystis jirovecii pneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab  Academic Article
• A halotyrosine antibody that detects increased protein modifications in asthma patients  Academic Article
• A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial  Academic Article
• A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*  Academic Article
• A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection  Academic Article
• A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer  Academic Article
• A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors  Academic Article
• A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226  Academic Article
• A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis  Academic Article
• A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial  Academic Article
• A real‐world, observational study of erenumab for migraine prevention in Canadian patients  Academic Article
• A review of cost–effectiveness of palivizumab for respiratory syncytial virus  Academic Article
• Abelacimab for Prevention of Venous Thromboembolism  Academic Article
• Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet  Academic Article
• Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies  Academic Article
• Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis  Academic Article
• Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial  Academic Article
• Adjuvant targeted therapy in early breast cancer  Academic Article
• Adjuvant therapy for early breast cancer: where do we stand today?  Academic Article
• Adjuvant therapy of the very young woman  Conference Paper
• Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review  Academic Article
• Adverse Gastrointestinal Events with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Nested Case–Control Study  Academic Article
• Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study  Academic Article
• Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study  Academic Article
• An Open Letter to Health Canada  Academic Article
• An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.  Academic Article
• Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience  Academic Article
• Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis  Academic Article
• Anti-TNFα therapy in immune-mediated subfertility: State of the art  Academic Article
• Anti-cytokine targeted therapies for ANCA-associated vasculitis  Academic Article
• Antiangiogenic Therapies in Non-Small-Cell Lung Cancer  Academic Article
• Antidotes for Novel Oral Anticoagulants  Academic Article
• Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease  Academic Article
• Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics  Academic Article
• Anti–Interleukin-5 Monoclonal Antibody to Treat Severe Eosinophilic Asthma  Academic Article
• Are late preterm infants as susceptible to RSV infection as full term infants?  Academic Article
• Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial  Academic Article
• Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose  Academic Article
• Asthma exacerbations on benralizumab are largely non‐eosinophilic  Academic Article
• Atypical Femoral Fractures: A Teaching Perspective  Academic Article
• BDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer  Academic Article
• Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study  Academic Article
• Bell's palsy in a patient receiving adalimumab for Crohn's disease  Academic Article
• Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma  Academic Article
• Benralizumab for Prednisone-Dependent Eosinophilic Asthma Associated With Novel STAT3 Loss of Function Mutation  Academic Article
• Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity  Academic Article
• Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial  Academic Article
• Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.  Academic Article
• Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis  Academic Article
• Biologic survival.  Academic Article
• Biosimilars for psoriasis: clinical studies to determine similarity  Academic Article
• Bleeding Complications and Management on anticoagulant therapy  Academic Article
• Briakinumab  Academic Article
• Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors  Academic Article
• CARESS: The Canadian Registry of Palivizumab  Academic Article
• CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation  Academic Article
• COMMENTARY: Should Anti-TNF-α Therapy be Offered to Patients with Infertility and Recurrent Spontaneous Abortion?*  Academic Article
• Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed  Academic Article
• Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease  Academic Article
• Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC  Academic Article
• Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease  Academic Article
• Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration  Academic Article
• Canakinumab After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation  Academic Article
• Cardiac Troponin Cutoffs: The Importance of Assay Sensitivity and the Patient Population  Academic Article
• Cardiac and Inflammation Biomarker Profile after Initiation of Adjuvant Trastuzumab Therapy  Academic Article
• Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial  Academic Article
• Cetuximab in Metastatic Squamous Cell Cancer of the Skin: A Swiss Case Series  Academic Article
• Changing costs and the impact on RSV prophylaxis  Academic Article
• Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis  Academic Article
• Clinical implications of reversal agents for direct oral anticoagulants  Academic Article
• Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis  Academic Article
• Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer  Academic Article
• Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis  Academic Article
• Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials  Academic Article
• Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants  Academic Article
• Connective-Tissue Growth Factor Contributes to TGF-β1–induced Lung Fibrosis  Academic Article
• Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?  Academic Article
• Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis  Academic Article
• Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective  Academic Article
• Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective  Academic Article
• Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis  Academic Article
• Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada  Academic Article
• Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey.  Academic Article
• Current strategies in the prevention of respiratory syncytial virus disease  Academic Article
• Cytokine-Based Therapy in Psoriasis  Academic Article
• Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery  Academic Article
• Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment  Academic Article
• Dabigatran Reversal with Idarucizumab  Academic Article
• Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature  Academic Article
• Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab  Academic Article
• Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing  Academic Article
• Denosumab treatment for fibrous dysplasia  Academic Article
• Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis  Academic Article
• Denosumab: mechanism of action and clinical outcomes  Academic Article
• Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran  Academic Article
• Detection of Pulmonary Emboli With ^99mTc-Labeled Anti–D-dimer (DI-80B3)Fab′ Fragments (ThromboView)  Academic Article
• Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease  Academic Article
• Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus  Academic Article
• Diretrizes Brasileiras para o tratamento farmacológico de pacientes hospitalizados com COVID-19  Academic Article
• Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?  Academic Article
• Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones  Academic Article
• Dupilumab, severe asthma airway responses, and SARS‐CoV‐2 serology  Academic Article
• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial  Academic Article
• Early and late changes in markers of aortic stiffness with breast cancer therapy  Academic Article
• Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme  Academic Article
• Eculizumab for treatment of asthma  Academic Article
• Eculizumab in a Patient with Dense-Deposit Disease  Academic Article
• Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer  Academic Article
• Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis  Academic Article
• Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia  Academic Article
• Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer  Academic Article
• Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty  Academic Article
• Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study  Academic Article
• Effectiveness at 1 Year of Monthly versus Variable-Dosing Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration  Academic Article
• Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia  Academic Article
• Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis  Academic Article
• Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma  Academic Article
• Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials  Academic Article
• Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance  Academic Article
• Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study  Academic Article
• Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses  Academic Article
• Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma  Academic Article
• Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma  Academic Article
• Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma  Academic Article
• Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma  Academic Article
• Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial  Academic Article
• Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis  Academic Article
• Efficacy of Intravenous Reslizumab in Oral Corticosteroid–Dependent Asthma  Academic Article
• Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma  Academic Article
• Emicizumab and thrombosis: The story so far  Academic Article
• Emicizumab state‐of‐the‐art update  Academic Article
• Evolocumab in HIV-Infected Patients With Dyslipidemia  Academic Article
• Exacerbations of Severe Asthma While on Anti–IL-5 Biologics  Academic Article
• Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial  Academic Article
• First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study  Academic Article
• First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients  Academic Article
• Fractionation of bovine serum albumin and monoclonal antibody alemtuzumab using carrier phase ultrafiltration  Academic Article
• Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis  Academic Article
• Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer  Academic Article
• Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies  Academic Article
• Granulocyte–macrophage colony‐stimulating factor ( GM ‐ CSF ) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐ GM ‐ CSF monoclonal antibody  Academic Article
• HER2 Testing in a Population-Based Study of Patients With Metastatic Breast Cancer Treated With Trastuzumab  Academic Article
• Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study  Academic Article
• Hematopoietic Processes in Eosinophilic Asthma  Academic Article
• Herceptest: Her2 expression and gene amplification in non-small cell lung cancer  Academic Article
• High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention  Academic Article
• Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease  Academic Article
• Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab  Academic Article
• How can we reverse bleeding in patients on direct oral anticoagulants?  Academic Article
• Idarucizumab  Academic Article
• Idarucizumab for Dabigatran Reversal  Academic Article
• Idarucizumab for Dabigatran Reversal — Full Cohort Analysis  Academic Article
• Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds  Academic Article
• Idarucizumab for dabigatran overdose  Academic Article
• Identifying and Ensuring Optimal Care for All Children at Risk of Developing Serious Respiratory Syncytial Virus Disease: A Canadian Nurses’ Perspective  Academic Article
• Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review  Academic Article
• Immune Thrombocytopenia Associated with Efalizumab Therapy for Psoriasis  Academic Article
• Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.  Academic Article
• Immunotherapies in Dermatologic Disorders  Academic Article
• Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis  Academic Article
• In COVID-19, tocilizumab reduces all-cause mortality at 28 d  Academic Article
• In patients hospitalized for COVID-19, tocilizumab reduces mortality at 28 d  Academic Article
• In patients with rheumatoid arthritis, bDMARD therapy was not associated with malignant neoplasms  Academic Article
• Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study  Academic Article
• Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors  Academic Article
• Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck  Academic Article
• Indirect comparison: relative risk fallacies and odds solution  Academic Article
• Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab  Academic Article
• Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context  Academic Article
• Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)  Academic Article
• Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.  Academic Article
• JAVELIN: avelumab another spear to fight urothelial carcinoma  Academic Article
• KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation  Academic Article
• LDP-02 (Millenium).  Academic Article
• Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31  Academic Article
• Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markers  Academic Article
• Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors’ reply  Academic Article
• Locally advanced breast cancer in octogenarian women  Academic Article
• Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17  Academic Article
• Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study  Academic Article
• Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial  Academic Article
• Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes  Academic Article
• Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials  Conference Paper
• Managing drug shortages during a pandemic: tocilizumab and COVID-19  Academic Article
• Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial  Academic Article
• Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia  Academic Article
• Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial  Academic Article
• Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease  Academic Article
• Metastatic renal cell cancer treatments: An indirect comparison meta-analysis  Academic Article
• MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies  Academic Article
• Monitoring and reversal of direct oral anticoagulants  Academic Article
• NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer  Academic Article
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank  Academic Article
• Nail Psoriasis and Biologics  Academic Article
• Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma  Academic Article
• Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy  Academic Article
• Normalisation of MRI ventilation heterogeneity in severe asthma by dupilumab  Academic Article
• Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis.  Academic Article
• Novel method for differentiation between Trastuzumab and host adaptive response  Academic Article
• Novel oral anticoagulants and reversal agents: Considerations for clinical development  Academic Article
• Novel targeted therapies for eosinophilic disorders  Academic Article
• Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis  Academic Article
• Omalizumab and the immune system: an overview of preclinical and clinical data  Academic Article
• Omalizumab for asthma in adults and children  Academic Article
• Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium  Academic Article
• Optimizing the Delivery of Targeted Research: An Opportunity for Comparative Effectiveness Research  Academic Article
• Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma  Academic Article
• Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer  Academic Article
• Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial  Academic Article
• Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes  Academic Article
• Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?  Academic Article
• Parameter scanning ultrafiltration: Rapid optimisation of protein separation  Academic Article
• Patient outcomes after anti TNF-α drugs for Crohn’s disease  Academic Article
• Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial  Conference Paper
• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial  Academic Article
• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial  Conference Paper
• Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study  Academic Article
• Pexelizumab Does Not “Complement” Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction  Academic Article
• Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study  Academic Article
• Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel  Academic Article
• Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation  Academic Article
• Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy  Academic Article
• Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors  Academic Article
• Plant-Produced Trastuzumab Inhibits the Growth of HER2 Positive Cancer Cells  Academic Article
• Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition  Academic Article
• Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics  Academic Article
• Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial  Academic Article
• Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab  Academic Article
• Preparative separation of monoclonal antibody aggregates by cation-exchange laterally-fed membrane chromatography  Academic Article
• Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis  Academic Article
• Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma  Academic Article
• Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102  Academic Article
• Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck  Academic Article
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival  Academic Article
• Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer  Conference Paper
• Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis  Academic Article
• Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy  Academic Article
• Ranibizumab and the eye  Academic Article
• Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.  Academic Article
• Reslizumab for Poorly Controlled, Eosinophilic Asthma  Academic Article
• Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study  Academic Article
• Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations  Academic Article
• Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study  Academic Article
• Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries  Academic Article
• Reversal agents for non-vitamin K antagonist oral anticoagulants  Academic Article
• Reversal of Direct Oral Anticoagulants: Current Status and Future Directions  Academic Article
• Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum  Academic Article
• Reversal of direct oral anticoagulants: a practical approach  Academic Article
• Review of Systemic Treatment Options for Adult Atopic Dermatitis  Academic Article
• Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada  Academic Article
• Role of Biologics in Asthma  Academic Article
• Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma  Academic Article
• Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma  Academic Article
• Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study  Academic Article
• Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial  Academic Article
• Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression  Academic Article
• Safety of bevacizumab in metastatic breast cancer patients undergoing surgery  Academic Article
• Sample sizes for clinical trials using sputum eosinophils as a primary outcome  Academic Article
• Seasonal Respiratory Syncytial Virus Prophylaxis Based on Predetermined Dates Versus Regional Surveillance Data  Academic Article
• Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab  Academic Article
• Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)  Academic Article
• Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study  Academic Article
• Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials  Academic Article
• Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study  Academic Article
• Separation of monoclonal antibody alemtuzumab monomer and dimers using ultrafiltration  Academic Article
• Specific antidotes for bleeding associated with direct oral anticoagulants  Academic Article
• Sputum Hyaluronan and Versican in Severe Eosinophilic Asthma  Academic Article
• Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial  Academic Article
• Stroke Rates after Introduction of Vascular Endothelial Growth Factor Inhibitors for Macular Degeneration: A Time Series Analysis  Academic Article
• Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous  Academic Article
• Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease  Academic Article
• Systematic review and meta‐analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease  Academic Article
• Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis  Academic Article
• Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update  Academic Article
• Targeted therapy for metastatic renal cell carcinoma  Academic Article
• Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1  Academic Article
• Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?  Academic Article
• The Demise of Anti–IL-5 for Asthma, or Not  Academic Article
• The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations  Academic Article
• The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation  Academic Article
• The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut  Academic Article
• The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium  Academic Article
• The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial  Academic Article
• The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence  Academic Article
• The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic  Academic Article
• The cost effectiveness of palivizumab: a systematic review of the evidence  Academic Article
• The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis  Academic Article
• The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies  Academic Article
• The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma  Academic Article
• The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study  Academic Article
• Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature  Academic Article
• Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma  Academic Article
• Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19  Academic Article
• Tocilizumab versus the Covid19 tempest: All’s well that ends well or much ado about nothing?  Academic Article
• Transitioning Between Brodalumab and Secukinumab in Moderate to Severe Psoriasis: An Early Look.  Academic Article
• Trastuzumab Cardiac Side Effects: Only Time Will Tell  Academic Article
• Treatment of severe facial psoriasis with adalimumab.  Academic Article
• Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk  Academic Article
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial  Academic Article
• Ustekinumab associated thrombotic thrombocytopenic purpura  Academic Article
• Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab  Academic Article
• When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH  Academic Article